The Feasibility and Utility of Harnessing Digital Health to Understand Clinical Trajectories in Medication Treatment for Opioid Use Disorder: D-TECT Study Design and Methodological Considerations

Abstract

IntroductionAcross the U.S., the prevalence of opioid use disorder (OUD) and the rates of opioid overdoses have risen precipitously in recent years. Several effective medications for OUD (MOUD) exist and have been shown to be life-saving. A large volume of research has identified a confluence of factors that predict attrition and continued substance use during substance use disorder treatment. However, much of this literature has examined a small set of potential moderators or mediators of outcomes in MOUD treatment and may lead to over-simplified accounts of treatment non-adherence. Digital health methodologies offer great promise for capturing intensive, longitudinal ecologically-valid data from individuals in MOUD treatment to extend our understanding of factors that impact treatment engagement and outcomes.MethodsThis paper describes the protocol (including the study design and methodological considerations) from a novel study supported by the National Drug Abuse Treatment Clinical Trials Network at the National Institute on Drug Abuse (NIDA). This study (D-TECT) primarily seeks to evaluate the feasibility of collecting ecological momentary assessment (EMA), smartphone and smartwatch sensor data, and social media data among patients in outpatient MOUD treatment. It secondarily seeks to examine the utility of EMA, digital sensing, and social media data (separately and compared to one another) in predicting MOUD treatment retention, opioid use events, and medication adherence [as captured in electronic health records (EHR) and EMA data]. To our knowledge, this is the first project to include all three sources of digitally derived data (EMA, digital sensing, and social media) in understanding the clinical trajectories of patients in MOUD treatment. These multiple data streams will allow us to understand the relative and combined utility of collecting digital data from these diverse data sources. The inclusion of EHR data allows us to focus on the utility of digital health data in predicting objectively measured clinical outcomes.DiscussionResults may be useful in elucidating novel relations between digital data sources and OUD treatment outcomes. It may also inform approaches to enhancing outcomes measurement in clinical trials by allowing for the assessment of dynamic interactions between individuals' daily lives and their MOUD treatment response.Clinical Trial RegistrationIdentifier: NCT04535583.

Overdose Detection Technologies to Reduce Solitary Overdose Deaths: A Literature Review

“…These various tools are tailored to the priorities and needs of people who use drugs wherever possible, such as maintaining anonymity and confidentiality, and respecting personal preferences regarding bystander response and other types of support provided. The newest developments in technology-based contingency management provide improved scalability and lower costs than prior contingency management approaches [9]. As discussed below, ODTs can be grouped into three categories: fixed-location devices requiring physical installation, mobile applications and hotlines, and wearable technology.…”

Patient Engagement in a Multimodal Digital Phenotyping Study of Opioid Use Disorder

“…The detailed design and protocol of the D-TECT study have been presented elsewhere [ 27 ]. Briefly, this observational study collected multiple streams of digital data over a 12-week study period—EMA data from a smartphone app, passive sensor data through a smartphone and a smartwatch, and social media data from participants’ social media accounts.…”

The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents

“…More than one outcome in a trial is desirable, as one outcome only can hardly provide a comprehensive clinical picture, yet adjusting for multiple comparisons in the statistical analyses is needed in case that more than one primary outcome is be­ing assessed or in case that inferential statistical testing is desired even of key secondary outcomes. For secondary and exploratory, hypothesis‐generating outcomes and those requiring a lot of multidimensional data, such as for functioning, modern tools including digital phenotyping and ecological momentary assessment can be of great value and should be progressively introduced in assessment of trials 218‐228 . Digital phenotyping and ecological momentary assessments can be repeated mul­tiple times, and can be even continuous in case of passive monitoring.…”